Study: Brain, immune system changes seen with chronic pain | Texas study to examine benefits, problems with cryotherapy | Researchers find pressure points, triggers for fibromyalgia
February 3, 2016
News for the pain professional

Pain Research NewsAdvertisement
Study: Brain, immune system changes seen with chronic pain
Chronic pain can bring about changes in DNA methylation in the immune system and brain, according to a McGill University study published in Scientific Reports. Researchers said they were surprised to see hundreds to thousands of genes marked by chronic pain. "We can now consider the implications that chronic pain might have on other systems in the body that we don't normally associate with pain," said researcher Moshe Szyf. (1/28)
Share: LinkedInTwitterFacebookGoogle+Email
Texas study to examine benefits, problems with cryotherapy
University of Texas researchers are studying the benefits and problems associated with cryotherapy, used as a treatment for pain relief and recovery, most often by athletes. The National Institutes of Health has awarded the study a $1.1 million grant. A woman died last year after using a cryotherapy chamber unsupervised. Engadget (2/1)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
Do passwords really protect your PDF?
Read this infographic to find out how password protection failures can make you:
• Lose data by people sharing passwords with others, especially through email.
• Lack the ability of knowing if an unauthorized person has read your files.
• Have PDFs with passwords that are easy to crack within minutes.
Download the free infographic now.

Treatment News
Study: Guideline cuts opioid prescribing in acute care setting
Temple University Hospital researchers say a guideline for prescribing opioid medications aimed at promoting safety and preventing abuse significantly decreased opioid prescriptions for patients with minor and chronic non-cancer pain in acute care settings. The study in the Journal of Emergency Medicine found the opioid prescribing rate dropped from 52.7% to 29.8% right after implementation of the guideline, and was at 33.8% a year to 18 months later. HCPLive (1/29)
Share: LinkedInTwitterFacebookGoogle+Email
Migraine treatment from Avanir gets FDA OK
Avanir Pharmaceuticals' Onzetra Xsail has been approved by the FDA to treat adult patients who are diagnosed with acute migraine with or without aura. The medication contains sumatriptan powder and is administered through the Xsail Breath Powered Delivery Device, which uses the patient's breath to deliver the medication into the nasal cavity for more efficient absorption. Practical Pain Management (2/1)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
Policy & Trends
Obama's 2017 budget plan calls for drug addiction treatment, prevention
President Barack Obama has included $1 billion in his 2017 budget plan to increase access to heroin- and opioid-addiction treatment for two years. The proposal also seeks about $500 million to help the Justice Department and HHS expand drug overdose prevention efforts. Part of the funding would go to an HHS project promoting buprenorphine prescriptions by nurse practitioners and physician assistants. MedPage Today (free registration) (2/2), McClatchy Washington Bureau (2/2)
Share: LinkedInTwitterFacebookGoogle+Email
Center requires pain contract for narcotics
SwedishAmerican Medical Group in Rockford, Ill., will have patients sign a pain contract when they receive a prescription for a long-term narcotic medication in an effort to prevent drug abuse. Drug testing will be conducted to monitor prescription use. Hospital President Thomas Schiller said most patients have understood the measures, and said they are focused on safety and not intended to be punitive. (Rockford, Ill.) (2/2)
Share: LinkedInTwitterFacebookGoogle+Email
APS News
Last chance to apply for the Rita Allen Foundation Award in Pain
The Rita Allen Foundation (RAF) and APS together may award two grants in the amount of $50,000 annually, for a period of up to three years to those research proposals demonstrating the greatest merit and potential for success. Eligible candidates will have completed their training and provided persuasive evidence of distinguished achievement or extraordinary promise in basic science research in pain. A complete application must be submitted via the proposalCENTRAL system by 11:59 p.m. Midnight Eastern Time on Feb. 8. Learn more.
Share: LinkedInTwitterFacebookGoogle+Email
Register early for the 2016 Annual Scientific Meeting and save $100!
Come to Austin, Texas, May 11-14 to connect with pain professionals with your same purpose and passion: translating research into relief. This meeting unites pain specialists to collaborate on innovative and grand-breaking research. New this year: A pre-conference event on Analgesic Trials will be held Wednesday, May 11. This one-day event will gather world-renowned experts in clinical trial conduct to convey current best practices; discuss experimental methods that increase analgesic trial assay sensitivity; highlight common clinical pain models and discuss their pros/cons; and provide networking opportunities for future collaboration. This pre-conference session will discuss methods to optimize the complex process of analgesic drug development. Don't miss out on the premier pain event of 2016 and register before March 11 to save $100! Register now.
Share: LinkedInTwitterFacebookGoogle+Email
Your days are numbered. Use them to throw open the windows of your soul to the sun. If you do not, the sun will soon set, and you with it."
-- Marcus Aurelius,
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about APS ->Membership | Annual Meeting | Education | Funding Opportunities | About Us
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Advertising:  Wynn Hansen
  P: 202.470.1149
Editor:  Tom Parks

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information